Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Betting On Regeneron Pharmaceuticals Inc (REGN)

Page 1 of 2

The market has been volatile as the Federal Reserve winds down its easy money policies. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 14 percentage points between June 25th and the end of October. SEC filings and hedge fund investor letters indicate that the smart money seems to be paring back their overall long exposure, and the funds’ movements is one of the reasons why the major indexes have retraced. In this article, we analyze what the smart money thinks of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and find out how it is affected by hedge funds’ moves.

Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a great stock to buy now? Investors who are in the know are taking an optimistic view. The number of long hedge fund positions rose by 3 in recent months. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article, we will examine companies such as The TJX Companies, Inc. (NYSE:TJX), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), and General Motors Company (NYSE:GM) to gather more data points.

Follow Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Trade (NASDAQ:REGN) Now!

If you’d ask most stock holders, hedge funds are perceived as underperforming, outdated financial vehicles of years past. While there are more than 8000 funds in operation at the moment, Our researchers look at the masters of this club, about 700 funds. These money managers control most of all hedge funds’ total asset base, and by observing their highest performing investments, Insider Monkey has unearthed many investment strategies that have historically exceeded the S&P 500 index. Insider Monkey’s small-cap hedge fund strategy outrun the S&P 500 index by 12 percentage points annually for a decade in their back tests.

With all of this in mind, let’s take a look at the latest action regarding Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

What does the smart money think about Regeneron Pharmaceuticals Inc (NASDAQ:REGN)?

At the end of Q3, a total of 32 of the hedge funds tracked by Insider Monkey were bullish on this stock, an increase of 10% from the previous quarter. With hedgies’ sentiment swirling, there exists a select group of notable hedge fund managers who were boosting their holdings significantly (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Samuel Isaly’s OrbiMed Advisors has the largest position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN), worth close to $226.8 million, corresponding to 2.3% of its total 13F portfolio. Coming in second is Citadel Investment Group, managed by Ken Griffin, which holds a $131 million call position; 0.1% of its 13F portfolio is allocated to the company. Some other professional money managers that hold long positions contain Jerome Pfund and Michael Sjostrom’s Sectoral Asset Management, John Overdeck and David Siegel’s Two Sigma Advisors, and D E Shaw.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!